CHU Brest
Brest, 29200, France
Not Yet Recruiting
NCT Number: NCT07640373
Coping Strategies, Loneliness, and Resilience in Patients With Dermatosis
The European Society for Dermatology & Psychiatry (ESDaP) studies the connection between the skin and the mind. Two previous studies of this type were conducted in 13 and 15 European countries, respectively. The first study assessed the psychological impact of skin diseases (anxiety, depression, sleep disorders), and the second analyzed feelings of stigma, stress, and body dysmorphic disorder (an abnormal perception of one's body).
In this study, new psychological variables will be examined: coping strategies, loneliness, and resilience.
A total of 23 centers will participate in the ESDaP3 study, located in 15 European countries (Austria, France, Germany, Hungary, Italy, North Macedonia, the Netherlands, Norway, Poland, Spain, Sweden, Switzerland, Turkey, and the United Kingdom).
The aim of this study is to examine coping strategies, loneliness, and resilience among patients with a skin condition. Coping strategies refer to the various ways a person uses to manage a difficult or stressful situation. Resilience refers to a person's ability to cope with difficult situations, adapt to changes or challenges, and regain a sense of balance despite obstacles. Other factors will be assessed: sleep, anxiety and depression, and quality of life. A questionnaire will be given to your potential partner to assess the impact of the skin condition on their life at this time.
At the study's sole French site, Brest University Hospital, 250 patients with a skin condition and 125 people without a skin condition will be enrolled.
Not Yet Recruiting
Trial opening soon.
Get NotifiedKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
About this study
At the time of enrollment, the following data will be collected:
- Demographic data: initials (first and last name); age; gender; educational level; marital status; employment status; socioeconomic status.
- General health status: EQ-5D-5L (VAS scale), suicidal thoughts, medical history (chronic skin disease, cardiovascular disease, pulmonary disease, diabetes, rheumatological disease, psychiatric illness)
- Clinical data: Questions about the skin condition: duration, severity over the past year, current severity, frequency of flare-ups, current location of lesions, presence and intensity of pruritus, presence of associated sensations
Self-report questionnaires:
- Coping strategies: Brief COPE questionnaire (dispositional format)
- Loneliness: UCLA Loneliness Scale (ULS-8)
- Resilience: Brief Resilience Scale (BRS)
- Sleep: Insomnia Severity Index Questionnaire (ISI)
- Anxiety: Generalized Anxiety Disorder 2 (GAD-2)
- Depression: Patient Health Questionnaire-2 (PHQ-2)
- Quality of life: Dermatology Life Quality Index (DLQI)
- Well-being: Skin Well-Being Scale
- Impact of dermatosis on the partner: FROM-16 (Family Reported Outcome Measure-16)
The estimated time to complete the questionnaires is 20 minutes; this will also be the duration of participation in this study.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Patients with skin conditions (inflammatory, autoimmune, cancerous, or genetic skin disorders)
- Controls: individuals without skin disease
- Adult participant
- Participant enrolled in a Social Security system or equivalent
- Participant who has given consent to participate in the study
Exclusion criteria
- Participants who are unable to understand the protocol
- Participants under legal guardianship (guardianship, conservatorship)
- Participants subject to a future protection order, family authorization, or court-ordered protection
- Participants who are unable to complete the questionnaires
Treatment and study plan
questionnaires
Other- Coping strategies: Brief COPE questionnaire (dispositional format)
- Loneliness: UCLA Loneliness Scale (ULS-8)
- Resilience: Brief Resilience Scale (BRS)
- Sleep: Insomnia Severity Index Questionnaire (ISI)
- Anxiety: Generalized Anxiety Disorder 2 (GAD-2)
- Depression: Patient Health Questionnaire-2 (PHQ-2)
- Quality of life: Dermatology Life Quality Index (DLQI)
- Well-being: Skin Well-Being Scale
- Impact of dermatosis on the partner: FROM-16
Primary outcomes
-
To assess adaptive coping in patients with skin conditions and compare them to those of a control group consisting of individuals with healthy skin.
Time frame: 1 day
Brief Coping Orientation to Problems Experienced Inventory (Brief COPE inventory) questionnaire (dispositional format) :
The questionnaire contains 28 items, divided into 14 coping strategies (2 items per strategy); each item is rated on a scale of 1 to 4:
- = I almost never do this
- = I do this sometimes
- = I do this often
- = I almost always do this
The analysis is conducted by subscale (each strategy), with scores ranging from 2 to 8.
The interpretation depends on the coping strategy being measured:
- for adaptive strategies, a high score is generally positive
- for less adaptive/dysfunctional strategies, a high score is generally negative
-
To assess loneliness in patients with skin conditions and compare them to those of a control group consisting of individuals with healthy skin.
Time frame: 1 day
UCLA Loneliness Scale - short Form (ULS-8)
The questionnaire consists of 8 items, each rated on a scale of 1 to 4:
- = Never
- = Rarely
- = Sometimes
- = Often
A high score indicates a high level of loneliness.
-
To assess resilience in patients with skin conditions and compare them to those of a control group consisting of individuals with healthy skin.
Time frame: 1 day
Brief Resilience Scale (BRS), it consists of 6 items.
Each item is rated on a scale of 1 to 5:
- = Strongly disagree
- = Disagree
- = Neither agree nor disagree
- = Agree
- = Strongly agree
The average of the 6 items is typically calculated (rather than the sum). Minimum score = 1, Maximum score = 5
A high score indicates greater resilience.
Secondary outcomes
-
Assess patients' sleep compared to controls.
Time frame: 1 day
Insomnia Severity Index Questionnaire (ISI)
The ISI consists of 7 items.
Each item is rated on a scale of 0 to 4:
0 = No problem
- = Mild
- = Moderate
- = Severe
- = Very severe
Total score: Minimum = 0, Maximum = 28
A high score indicates a more severe form of insomnia.
-
Assess patients' anxiety levels compared to controls.
Time frame: 1 day
Generalized Anxiety Disorder 2 (GAD-2)
The GAD-2 consists of 2 items.
Each item is scored on a scale of 0 to 3:
0 = Never
- = Several days
- = More than half the days
- = Almost every day
Total score: Minimum = 0, Maximum = 6
A high score indicates a higher level of anxiety.
-
Assess patients' depression levels compared to a control group.
Time frame: 1 day
Patient Health Questionnaire-2 (PHQ-2)
The PHQ-2 consists of 2 items.
Each item is scored on a scale of 0 to 3:
0 = Never
- = Several days
- = More than half the days
- = Almost every day
Total score: Minimum = 0, Maximum = 6
A high score indicates a higher level of depressive symptoms
-
Assess patients' quality of life in comparison with a control group.
Time frame: 1 day
Dermatology Life Quality Index (DLQI)
The DLQI consists of 10 items.
Each item is scored on a scale of 0 to 3:
0 = Not at all / Not applicable
- = A little
- = A lot
- = Very much
Total score: Minimum = 0, Maximum = 30
A high score indicates a greater impact of the skin condition on quality of life
-
Assess patients' well-being in comparison with a control group.
Time frame: 1 day
Skin Well Being Scale (SWBS)
The SWBS consists of 5 items.
Each item is rated on a scale of 0 to 5:
- All the time
- Most of the time
- More than half the time
- Less than half the time
- Sometimes
- Never
Total score: Minimum = 0, Maximum = 25
A lower score indicates better skin well-being.
-
Assessing the impact of dermatosis on the partner
Time frame: 1 day
Family Reported Outcome Measure (FROM-16)
The FROM-16 consists of 16 items.
Each item is rated on a scale of 0 to 2:
0 = Not at all
- = A little
- = A lot
Total score: Minimum = 0, Maximum = 32
A high score indicates a greater impact of the illness on the quality of life of family members.
Study contacts
Contact information is provided by the study sponsor or research team.
Sponsors and collaborators
Lead sponsor
University Hospital, Brest
Other
Collaborators
- Cardiff University
- Justus-Liebig University Gießen Medical Center
- Karolinska Institutet
- Leiden University Medical Center
- Lund University
- Malmö University
- Sisli Hamidiye Etfal Training and Research Hospital
- Szeged University
- The Royal London Hospital, UK
- Universidad de Zaragoza
- Universidade do Algarve
- University Hospital Muenster
- University of Amsterdam
- University of Bergen
- University of Graz
- University of La Laguna
- University of Rzeszow
- University of Skopje
- University of Stavanger
- Wroclaw Medical University
Registry information
Acronym: ESDaP3
Important dates
- Study start
- 2026
- Primary completion
- 2029
- Study completion
- 2029
- First posted
- Jun 10, 2026
- Registry last updated
- Jun 10, 2026
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Recruiting
Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma
NCT05561595
Body Weight, Cancer
Gainesville, Florida, United States
View Trial Details
Completed
Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy
NCT04283539
Cancer, Immunotherapy
Denver, Colorado, United States
View Trial Details
Enrolling by Invitation
The Skin Microbiota in Skin Disease and Eczema
NCT06924333
Dermatitis, Eczema
Lund, Skåne County, Sweden
View Trial Details
Recruiting
Dynamics of Dysbiosis in the Skin and Gut Microbiome of Burn Patients
NCT07209007
Burn Injuries, Burns
Seoul, South Korea
View Trial Details